In-vivo inhibition of neutral endopeptidase 1 results in higher absorbed tumor doses of [ 177 Lu]Lu-PP-F11N in humans: the lumed phase 0b study.

Christof RottenburgerMichael HentschelMarkus FürstnerLisa McDougallDanijela KottorosFelix KaulRosalba MansiMelpomeni FaniA Hans VijaRoger SchibliSusanne GeistlichMartin BeheEmanuel R ChristDamian Wild

Published in: EJNMMI research (2024)

Lu]Lu-PP-FF11N and consecutively increases radiation doses in tumors and organs. Trial registration clinicaltrails.gov, NCT03647657. Registered 20 August 2018.

Keyphrases

clinical trial
study protocol
phase iii
phase ii
radiation therapy
open label